The C1831 device category was made effective in the OPPS on October 1, 2021, and expired on September 30, 2024, as such, we cannot reinstate the pass-through payment status of C1831 because reinstatement would make the pass-through payment status effective longer than the maximum 3-year period permitted under section 1833(t)(6)(B)(iii) of the Act and 419.66(g)
Voprosy meditsinskoi khimii, 34(1), 5156
Based on the presence of three different receptors, i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), breast cancer is broadly categorized into 4 subtypes, i.e., basal/triple negative, HER2, luminal A, and luminal B
The options may be chosen on the product page FREQUENTLY ASKED QUESTIONS (FAQS) Some of the following are questions asked of us by customers